First-week expansion of activated peripheral B-cell subsets is associated with grade 3 or higher immune-related adverse events after nivolumab plus ipilimumab
这项前瞻性研究表明,在接受纳武利单抗联合伊匹单抗治疗的第一周内,激活的周围血 B 细胞亚群的扩增与随后发生的严重(3 级或更高)免疫相关不良事件显著相关,这提示早期 B 细胞监测可作为风险分层的潜在生物标志物。